Trial · NCT01705977
Adverse events660
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 660
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Herpes zoster | Infections and infestations | Placebo | 31 | 2,001 | 33 |
| other | Herpes zoster | Infections and infestations | Belimumab 10 mg/kg | 17 | 2,002 | 17 |
| serious | Pneumonia | Infections and infestations | Placebo | 27 | 2,001 | 28 |
| serious | Pneumonia | Infections and infestations | Belimumab 10 mg/kg | 18 | 2,002 | 18 |
| serious | Urinary tract infection | Infections and infestations | Placebo | 8 | 2,001 | 9 |
| serious | Urinary tract infection | Infections and infestations | Belimumab 10 mg/kg | 16 | 2,002 | 17 |
| serious | Lupus nephritis | Renal and urinary disorders | Placebo | 11 | 2,001 | 11 |
| serious | Lupus nephritis | Renal and urinary disorders | Belimumab 10 mg/kg | 6 | 2,002 | 6 |
| serious | Systemic lupus erythematosus | Musculoskeletal and connective tissue disorders | Placebo | 11 | 2,001 | 12 |
| serious | Systemic lupus erythematosus | Musculoskeletal and connective tissue disorders | Belimumab 10 mg/kg | 5 | 2,002 | 6 |
| serious | Cellulitis | Infections and infestations | Placebo | 8 | 2,001 | 8 |
| serious | Cellulitis | Infections and infestations | Belimumab 10 mg/kg | 7 | 2,002 | 7 |
| serious | Gastroenteritis | Infections and infestations | Placebo | 11 | 2,001 | 11 |
| serious | Gastroenteritis | Infections and infestations | Belimumab 10 mg/kg | 4 | 2,002 | 5 |
| serious | Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Placebo | 7 | 2,001 | 7 |
| serious | Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | Belimumab 10 mg/kg | 2 | 2,002 | 2 |
| serious | Acute kidney injury | Renal and urinary disorders | Placebo | 6 | 2,001 | 6 |
| serious | Acute kidney injury | Renal and urinary disorders | Belimumab 10 mg/kg | 2 | 2,002 | 2 |
| serious | Pyrexia | General disorders | Placebo | 6 | 2,001 | 6 |
| serious | Pyrexia | General disorders | Belimumab 10 mg/kg | 2 | 2,002 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01705977/events